Self-Funded Health Reserving News.
Self-funded health IBNR turns over fast, but the cost drivers behind it do not: GLP-1 coverage, stop-loss pricing, PBM rules, and federal mandates. This feed tracks the developments that change what benefits CFOs should accrue.
New to reserving this line? Start with IBNR for Self-Funded Health Plans.
Latest in Health Plans.
Stop-Loss Reinsurance at 15% Signals a Multi-Year Rate Floor
Segal's Q3 2026 benchmarking report, drawing on 225 health plans, shows average stop-loss premiums up 12.7%, but the structural driver is a reinsurance correction cycle that carriers project will take three to five years to close, not one.
Medicaid Work Rule Took Effect July 31, Resetting Plan Frequency
The CMS interim final rule implementing Medicaid community engagement requirements became effective July 31, placing a January 1, 2027 state implementation deadline squarely inside the 2027 renewal window for self-insured health plans.
DOL MHPAEA Crackdown: Every Self-Funded Plan Initially Fails
DOL enforcement of mental health parity rules is producing a 100% initial failure rate on comparative analyses reviewed, creating a retroactive benefit liability that standard IBNR development cannot detect.
PwC Sets 2027 Medical Cost Trend at 9%, a 17-Year High
PwC's Behind the Numbers pegs the 2027 group medical trend at 9%, the highest since 2010. For a self-funded plan, trend is the dominant input to IBNR, so a plan still carrying 6% or 7% is already under-accrued, not just under-budgeted.
Segal: Stop-Loss Premiums Jump 13% as Leverage Bites
Segal's 2026 dataset shows specific stop-loss premiums up 12.7% for plans holding deductibles flat. The driver is leveraged trend: a fixed attachment point makes the reimbursed layer grow far faster than gross medical trend.
FTC Caremark Settlement Resets Self-Insured Rx Trend
The FTC's July 14 consent settlement with CVS Caremark restructures rebate flow and point-of-sale pricing across all drugs, resetting the net pharmacy trend and the rebate accrual lag that quietly drives self-funded plan IBNR.
Ortho and MSK Climb Into Stop-Loss High-Cost Top Three
Sun Life's 2026 high-cost claims report puts orthopedic and musculoskeletal conditions into the top tier of stop-loss claims. It is a frequency story, and it reshapes the attachment-point problem for self-funded plans.
FDA Fast-Track Program Raises Gene Therapy Claim Frequency
The FDA's National Priority Voucher pilot has cut some gene-therapy reviews to one or two months, and the reserve variable it moves for self-funded plans is frequency, not severity.
FDA Pediatric Casgevy Approval Tests Stop-Loss Reserves
FDA's July 1 supplemental approval expanded Casgevy to patients aged 2 and older, moving a one-time gene therapy exposure into younger covered dependents and forcing self-funded plans to revisit stop-loss recovery timing.
Sixth Circuit PBM Ruling Tests Pharmacy Claim Reserves
The Sixth Circuit affirmed ERISA preemption of Tennessee PBM network and cost-sharing rules as applied to McKee Foods' self-funded health plan. The reserve issue is whether pharmacy channel controls still support the expected claim ratio and unpaid-claim completion factors.
CMS Drug Model Tests Health Plan Stop-Loss Assumptions
CMS has set a September 10, 2026 state application deadline for the GENEROUS Medicaid drug model. Self-insured employers are outside the model, but its public-payer net-price signal can distort pharmacy trend and stop-loss severity assumptions if plans do not tie benchmarks back to their own PBM contracts.
Cigna Drops GLP-1 for Own Staff as Employer Coverage Plateaus
Cigna will end GLP-1 weight-loss coverage for its 67,700 employees on July 1, the highest-profile signal that employer tolerance for GLP-1 pharmacy costs has peaked, forcing self-insured plan sponsors to model two divergent reserve scenarios.
Stop-Loss Claims Accelerate 9 Points Above Five-Year Trend
Tokio Marine HCC's 2026 Annual Market Report shows January 2025 specific claim trends running 9.2 percentage points above the prior five-year average, pressuring attachment point adequacy for self-insured health plans.
MHPAEA Rule Rewrite by Year-End Leaves Self-Funded Plans Guessing
The tri-agencies will propose a replacement MHPAEA rule by December 31, 2026, leaving self-funded plan sponsors unable to calibrate behavioral health utilization assumptions for plan-year 2027 budgets.
EBRI: Gene Therapy Reaches 9.2 per 100K in Employer Plans
EBRI's first large-scale employer-plan analysis finds cell and gene therapy utilization rose to 9.2 per 100,000 enrollees by 2022, giving self-insured plan sponsors a credible base rate for modeling catastrophic single-claim exposure in their IBNR estimates.
Lockton: Cost Focus Drives Self-Insured Plans to Retain More Risk
Lockton's 2026 survey of 1,705 employers finds cost control has overtaken talent retention as the top benefits priority, pushing self-insured plans toward higher attachment points and thinner stop-loss coverage while claim severity accelerates.
Comorbidities, Not Diagnosis, Push Self-Insured Claims Past $3M
Sun Life's 2026 stop-loss report finds secondary health conditions are the dominant cost driver above $3 million, exposing a structural gap in how self-insured plans model catastrophic claim risk at renewal.
ACA Enrollment Drops 4.8M, Pushing Risk to Self-Funded Plans
KFF projects ACA marketplace effectuated enrollment will fall from 22.3 million to 17.5 million in 2026 as enhanced subsidies expire, shifting risk pool composition and pent-up utilization into self-funded employer health plans.
FTC Consent Decree Opens Spread-Free Option at Express Scripts
A 10-year FTC consent decree requires Express Scripts to offer plan sponsors a standard option that eliminates spread pricing and bases member costs on net drug prices, creating a pharmacy IBNR reset opportunity for self-funded health plans before the January 1, 2027 implementation deadline.
ERISA Fiduciary Wave Reaches Self-Funded Health Plan Sponsors
Four class actions, a Supreme Court pleading shift, and a 12-state inquiry converge to create reservable fiduciary exposure for employers sponsoring self-funded health plans.
Nebraska Starts Medicaid Work Rules as Cost Shift to Plans Begins
Nebraska's May 1 launch of Medicaid work requirements begins a state-by-state coverage contraction that will push hospital cost-shifting and enrollment mix changes directly into self-insured health plan reserves.
Federal Law Now Requires Full PBM Rebate Pass-Through to Plans
The Consolidated Appropriations Act of 2026 mandates 100% rebate pass-through from PBMs to ERISA plan sponsors, rewiring the pharmacy cost structure that self-insured health plans have budgeted around for years.
GLP-1 Cost Surge Exposes Pharmacy and Stop-Loss Planning Gap
Per-member GLP-1 allowed costs surged 840% from 2022 to 2024, but most self-insured employers still manage pharmacy benefits and stop-loss strategy as separate exercises, missing how sustained utilization compounds into aggregate exposure.
DOL Parity Report Flags Self-Funded Plans for NQTL Gaps
The Tri-Agencies' fourth MHPAEA enforcement report documents 15 noncompliance findings and reminds self-funded plans that parity responsibility sits with the plan, not the TPA, raising behavioral health utilization assumptions for benefits directors modeling reserve impact.
$1M+ Claims Hit Half of Self-Insured Plans as Cancer Costs Surge
The 2025 Aegis Risk survey found 49% of self-insured employers now report at least one claimant exceeding $1 million, more than double the prior year, reshaping catastrophic claim frequency assumptions for stop-loss attachment and aggregate corridor calculations.
Gene Therapy's $4M Claims Are Testing Stop-Loss Attachment Points
Single claims of $3M to $4.5M are breaching specific stop-loss thresholds, and rising eligible-patient counts threaten to blow through aggregate corridors for self-insured health plans that set expected claim ratios without a gene therapy loading factor.
Lilly's $149 Oral GLP-1 Pill Forces Self-Insured Plans to Rethink Exclusions
Foundayo's $149 monthly price point collapses the cost barrier that kept oral GLP-1s off most self-insured formularies, forcing immediate revisions to pharmacy PMPM assumptions and stop-loss attachment points.
Medicare GLP-1 Bridge July 1 Pressures Employer Stop-Loss
Medicare's six-month demonstration covering Wegovy and Zepbound for obesity reshapes the expected claim ratio on Rx for self-insured health plans and forces a mid-year look at specific stop-loss attachment adequacy.
DOL PBM Fee Rule Targets Hidden Costs in Self-Insured Plans
A proposed DOL disclosure rule would force pharmacy benefit managers to reveal every dollar of compensation from ERISA self-insured plans, potentially lowering pharmacy reserve assumptions while creating new fiduciary liability exposure.
The Reserving Briefing.
One email a month for self-insureds and captives. Reserving fundamentals, method notes, and commentary on what's actually moving loss development this quarter.